Phospholipase A2 Receptor, Monitoring, Enzyme-Linked Immunosorbent Assay, Serum
Use
This test is useful for distinguishing primary from secondary membranous nephropathy and monitoring patients with membranous nephropathy over time for trends in anti-phospholipase A2 receptor antibody levels. Anti-PLA2R antibodies are highly specific for diagnosing primary membranous nephropathy, and their levels can correlate with disease activity and progression.
Special Instructions
Not provided.
Limitations
This test should not be used as a standalone test but an adjunct to other clinical information. Absence of circulating anti-phospholipase A2 receptor autoantibodies does not rule out a diagnosis of primary membranous nephropathy. A diagnosis should not be made based on a single test result.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Anti-PLA2R
Protein
LOINC Codes
- 73737-9 - PLA2R IgG Ser IA-aCnc
- 73737-9 - PLA2R IgG Ser IA-aCnc
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into plastic vial
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 14 days |
| Frozen | 14 days |